Alivus Life Sciences has announced a board meeting scheduled for January 22, 2026, to consider and approve the unaudited financial results for the quarter and nine months ended December 31, 2025. Additionally, the company has declared a trading window closure for designated persons from December 31, 2025, to January 24, 2026.
Board Meeting Announcement
Alivus Life Sciences has scheduled a meeting of its Board of Directors on January 22, 2026. The primary agenda is to review and approve the unaudited financial results. This review will cover the financial performance for the quarter and nine months that concluded on December 31, 2025.
Trading Window Closure
In compliance with regulations regarding insider trading, Alivus Life Sciences has announced the closure of its trading window for designated company personnel. The closure period spans from December 31, 2025, to January 24, 2026. This restriction is to ensure fairness and compliance during the period when the unaudited financial results are being finalized.
Source: BSE
